T-Cell Receptor Repertoire Profiling as a Predictive Biomarker for Immunotherapy in Unresectable Stage III Non-small Cell Lung (NSCLC)

Durvalumab is an immune checkpoint inhibitor used as the immunotherapy of locally advanced NSCLC (unresectable stage III). However, limited reports on immunological profile as prognostic factors have been found. Recently, T-cell receptor (TCR) repertoire profiling has emerged as a potential biomarker for predicting response to immunotherapy in NSCLC patient. This study explored the role of TCR repertoire as a predictive biomarker.